These findings further contribute to CHR’s world-wide reputation as a innovator in infertility treatments.
New York, NY (PRWEB) July 9, 2010
A study conducted by Adrian Shulman, MD and co-workers of Tel Aviv University in Tel Aviv, Israel, confirmed previously published research by New York City’s Center for Human Reproduction (CHR) about the positive effects of the supplement dehydroepiandrosterone (DHEA) in improving fertility in women with diminished ovarian reserve. Dr. Shulman’s study, which featured only 33 women, 17 on DHEA and 16 controls, represents the first prospectively randomized study of DHEA in infertility. It confirmed prior published reports from CHR that DHEA increases the likelihood of conception with in vitro fertilization (IVF) approximately threefold.
New York’s CHR pioneered the use of DHEA and has been using DHEA supplementation in women with diminished ovarian reserve since 2004. CHR researchers, under the leaderships of Norbert Gleicher, MD, the center’s Medical Director, and David H. Barad, MD, its Director of Clinical Assisted Reproduction, previously published a number of controlled studies of various designs demonstrating the benefits of DHEA in increasing fertility in prestigious peer-reviewed medical journals – such as Fertility and Sterility, Human Reproduction and the Journal of Assisted Reproduction and Genetics – which contributed to the increasing popularity of DHEA supplementation world-wide. CHR’s prior studies are, indeed, fully referenced in the scientific paper by Shulman and associates, though left unmentioned in the press release, accompanying publication of their study.
Based on prior research CHR, indeed, in 2009 was awarded a United States patent for the use of DHEA in treating infertility in women with diminished ovarian reserve. Over 2,000 women from all over the U.S. and the world so far received treatment with DHEA at CHR, either because of diminished ovarian reserve due to advanced age or premature ovarian aging. This comparatively very large experience contributes to CHR’s world-wide reputation as a “fertility center of last resort.”
By successfully recruiting 33 women into a prospectively randomized study, of which 17 received DHEA, Dr. Shulman’s group achieved a key research milestone that CHR, despite several attempts over six years, failed to realize. As, however, quoted in their paper, but omitted by the paper’s press release, researchers and physicians, including Dr. Shulman and associates, started utilizing DHEA worldwide only based on earlier CHR research and publications.
The study by Shulman and associates represents an important step forward in confirming the beneficial effects of DHEA in female infertility and the investigators are to be congratulated on their efforts.
Further information about CHR's DHEA treatments and research can be found by visiting: http://www.centerforhumanreprod.com/dhea.html
About Center for Human Reproduction
Center for Human Reproduction (CHR) is one of the leading fertility centers in the United States. A provider of fertility services to both men and women, CHR is also a research and educational organization, holding a number of patents in the field of human fertility. More information about CHR can be found online by visiting http://www.centerforhumanreprod.com or by calling 212-994-4400.